Clinical Trial

Pentoxifylline in Diabetic Kidney Disease

Study acronym: VA PTXRx
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Pentoxifylline (PTX) is a medication that has been on the market since 1984 for use in disease in the blood vessels of the legs. There is some preliminary information that it may protect the kidneys from damage due to diabetes and other diseases. "Pentoxifylline in Diabetic Kidney Disease" is a study to bee conducted in 40 VA hospitals across the nation to determine definitively whether or not PTX can prevent worsening of kidney disease and delay death in patients with diabetic kidney disease.
Protocol Amendment History 22 amendments
This ClinicalTrials.gov record has been amended 22 times since 2018-08-08; most recent amendment 2026-04-06.
Status change: Recruiting → Active, Not Recruiting 2025-12-12
Status change: Active, Not Recruiting → Recruiting 2020-08-10
Status change: Recruiting → Active, Not Recruiting 2020-04-06
Status change: Not Yet Recruiting → Recruiting 2019-11-21
Trial Details
NCT Number NCT03625648
Lead Sponsor VA Office of Research and Development
Conditions Diabetic Kidney Disease
Enrollment 2,376 participants
Start Date 2019-11-18
Primary Completion 2028-01-03 (estimated)
Study Completion 2030-07-08 (estimated)
Updated on ClinicalTrials.gov 2026-04-13